BC Innovations | Dec 6, 2019
Targets & Mechanisms

Emerging immuno-oncology mechanisms at ASH 2019

Researchers are finding new ways to monitor the immune system in hematologic diseases that could have implications for optimizing immuno-oncology therapies, according to BioCentury’s analysis of emerging targets at ASH 2019. In abstracts released ahead...
BC Innovations | May 7, 2015
Distillery Therapeutics

Therapeutics: Importin 7 (IPO7); MAP kinase 1 (MAPK1; ERK-2); MAPK3 (ERK-1)

Cancer INDICATION: Cancer In vitro and mouse studies suggest a peptide inhibitor of IPO7 binding to MAPK1 or MAPK3 could help treat cancer. In multiple human cancer cell lines, a cell-penetrating peptide derived from MAPK1...
BC Innovations | Jul 30, 2009
Distillery Therapeutics

Indication: Cardiovascular disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cardiovascular disease Hypertension Postmeiotic segregation increased 1 (PMS1); solute carrier family 24 sodium/potassium/calcium exchanger member 4 (SLC24A4); tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein, z-polypeptide (YWHAZ); importin 7...
BioCentury | Jul 13, 2009
Emerging Company Profile

NanoVector: Planted in the nucleus

NanoVector Inc. believes its plant virus-based nanoparticle technology will allow it to deliver drugs precisely inside targeted cells, reducing side effects and improving the efficacy of chemotherapeutics and other drugs. The technology exploits the chemical...
Items per page:
1 - 4 of 4